Reading SONM? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SONM free→Reading SONM? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SONM free→NASDAQInformation TechnologySoftware - InfrastructureSnapshot 2026-06-16
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is neutral. Earnings quality cannot be assessed since the company is unprofitable. Management's recent track record has been unsteady, with frequent changes. Risk is high, and the sector backdrop is a tailwind. Compared with sector peers, SONM is below typical. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $4.74. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Information Technology names rated neutral grew net income 54% of the time over the next year (vs 68% for the rest of the cohort, n=3704).
Over the trailing year it converted 1.18x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, long-term interest rates, real (inflation-adjusted) rates, the US dollar, Fed net liquidity.
37 material management or governance events in the past 24 months, led by M&A activity. Historically, Information Technology names rated volatile grew net income 58% of the time over the next year (vs 61% for the rest of the cohort, n=793).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
via XLK
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$447.
How much price usually moves either way.
On a bad day, this stock has moved -$1,332.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $9,132.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for SONM yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on August 22, 2025, the Company received a letter from the staff of the Nasdaq Listing Qualifications Department (the “Staff”) notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus peers.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
SONM DNA X INC | Typical Show detailsSector percentile: 39 of 100 | — | high |
Not investment advice. As of 2026-06-16.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Transition from monitoring and testing to marketing the trading platform to the public.
Newly stated in 2026-Q1. Management anticipates growth in revenue, gross margin, and profitability upon exiting the monitoring phase. However, no specific financial milestones or customer announcements were provided this quarter, indicating limited substantive delivery so far.
“We expect future growth in revenue, gross margin and profitability as we exit the monitoring and testing phase.”
Resolve issues related to non-compliance with Nasdaq Listing Rule 5550(b)(1) regarding stockholders' equity.
Newly stated in 2026-Q1. The company received a notice of non-compliance with Nasdaq Listing Rule 5550(b)(1), which requires maintaining stockholders' equity of at least $2,500,000. No specific actions or financial improvements were disclosed this quarter, indicating limited progress in addressing this regulatory issue.
“Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard.”
Focus on managing financial obligations and optimizing capital allocation strategies.
Newly stated in 2026-Q1. The company issued a convertible promissory note as part of its capital allocation strategy. However, with operating income at -$3.618M in 2026-Q1 and cash from operations at -$3.466M, financial obligations remain a challenge, indicating limited progress in optimizing capital allocation.
“Entry Into a Material Definitive Agreement. Securities Purchase Agreement; Issuance of Convertible Note.”
Entry Into a Material Definitive Agreement. Securities Purchase Agreement; Issuance of Convertible Note On May 20, 2026, DNA X, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with DNA Holdings Venture, Inc. (the “Purchaser”) pursuant to which the Company sold and issued to the Purchaser a convertible promissory note (the “Note”) in the principal amount of $3,052,787.68 for an aggregate purchase price in the same amount. The transactions contemplat…
Termination of a Material Definitive Agreement. As previously disclosed, on September 29, 2025, DNA X, Inc. (the “Company”) and Chardan Capital Markets LLC (“Chardan”) entered into a ChEF Purchase Agreement (the “ChEF Agreement”) pursuant to which Chardan committed to purchase, subject to certain limitations and conditions set forth in the ChEF Agreement, up to $500 million of shares of the Company’s common stock, par value $0.001 per share, and a Registration Rights Agreement (the “Registrat…
Results of Operations and Financial Condition. On May 20, 2026, DNA X, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2026 (the “Press Release”). A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Creation of a Direct Financial Obligation or an Obligation under an Off-Balane Sheet Arrangement of a Registrant. The information set forth in